The Petri Dish: Group eyes Biogen Alzheimer’s drug price, FDA rejects psych drug application


The FDA has elected not to accept a new drug application from Minerva Neurosciences Inc., sending shares plummeting. Read this, and more, in the latest biotech news roundup, The Petri Dish.

Previous Silver Line extension highlights big changes for D.C.-area travel and transit in 2022
Next The biggest Louisville restaurant openings in 2022, month-by-month